Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | ZDHHC2 | Q9UIJ5 | 1/20 | 0.34 |
| ▸ | FURIN | P09958 | 1/20 | 0.33 |
| ▸ | MGLL | Q99685 | 2/20 | 0.33 |
| ▸ | RECQL | P46063 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1151212 | 0.85 | KMT2A (0.40) | KMT2APOLBZDHHC2HSD17B10 | |
| SCHEMBL1151213 | 0.85 | KMT2A (0.40) | KMT2APOLBZDHHC2HSD17B10 | |
| SCHEMBL14996220 | 0.84 | ZDHHC2 (0.50) | ZDHHC2MGLL | |
| SCHEMBL3421932 | 0.84 | ZDHHC2 (0.50) | ZDHHC2MGLL | |
| SCHEMBL13630803 | 0.83 | ZDHHC2 (0.52) | ZDHHC2MGLL | |
| SCHEMBL13617146 | 0.82 | MAPT (0.40) | KMT2APOLBZDHHC2MGLLRECQL | |
| SCHEMBL29306423 | 0.82 | SMN1; SMN2 (0.46) | KMT2AL3MBTL1KDM4EHSD17B10 | |
| SCHEMBL13617147 | 0.81 | ZDHHC2 (0.36) | KMT2AL3MBTL1ZDHHC2MGLLRECQL | |
| SCHEMBL14996210 | 0.81 | HPGD (0.40) | KMT2AL3MBTL1ZDHHC2MGLL | |
| SCHEMBL24654021 | 0.80 | SMN1; SMN2 (0.37) | KMT2AL3MBTL1ZDHHC2MGLLRECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240226026-A1 | BRANCHED TAIL LIPID COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS | ARES CAPITAL CORPORATION, AS AGENT | 2024-07-11 | — | — | US | disclosed |
| WO-2022204288-A1 | BRANCHED TAIL LIPID COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS | MODERNATX, INC. (US) | 2022-09-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240226026-A1 | BRANCHED TAIL LIPID COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS | PLTP, LNPK, PLIN3 | KMT2A 4165/4885POLB 1805/4885L3MBTL1 53/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.